CN106676637B - A kind of DNA library and its application detecting osteochondroma multiple Disease-causing gene - Google Patents
A kind of DNA library and its application detecting osteochondroma multiple Disease-causing gene Download PDFInfo
- Publication number
- CN106676637B CN106676637B CN201610785555.0A CN201610785555A CN106676637B CN 106676637 B CN106676637 B CN 106676637B CN 201610785555 A CN201610785555 A CN 201610785555A CN 106676637 B CN106676637 B CN 106676637B
- Authority
- CN
- China
- Prior art keywords
- gene
- dna library
- osteochondroma
- disease
- library
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
- C40B40/04—Libraries containing only organic compounds
- C40B40/06—Libraries containing nucleotides or polynucleotides, or derivatives thereof
- C40B40/08—Libraries containing RNA or DNA which encodes proteins, e.g. gene libraries
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6869—Methods for sequencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pathology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The present invention discloses a kind of DNA library and its application that the mutation of osteochondroma multiple Disease-causing gene is detected by targeting high-throughput semiconductor sequencing technologies.Specifically, according to 15 osteochondroma multiple Disease-causing genes, design primer pond, super-multiplet PCR amplification is carried out to sample genomic dna, amplified production is sequenced using high-throughput semiconductor sequencing technologies, pathogenic mutation is found, provides the theoretical foundation of science of heredity and molecular biology for clinical diagnosis.Accurate, quick, flexible, low cost that the present invention has the characteristics that, 15 genetic test regions of the present invention cover all known Disease-causing genes of osteochondroma multiple comprehensively, have great significance to the diagnosis and differential diagnosis of osteochondroma multiple and clinical value.
Description
Technical field
The present invention relates to one kind to be caused a disease by targeting high-throughput semiconductor sequencing technologies checkout and diagnosis osteochondroma multiple
The DNA library and its application of gene.Specifically according to osteochondroma multiple Disease-causing gene, design can be covered outside said gene
The super-multiplet PCR primer of aobvious son and contiguous zone, and super-multiplet PCR amplification is carried out to sample genomic dna, amplified production utilizes
High throughput sequencing technologies are sequenced, and are found pathogenic mutation, are specified the genetic factors of osteochondroma multiple, are clinical diagnosis
The theoretical foundation of science of heredity and molecular biology is provided, the genetic test skill in field of biomedicine clinical detection technique is belonged to
Art.
Background technique
Osteochondroma multiple (Multiple osteochondromas, MO) also known as multiple exostosis are a kind of
Skeletal development is abnormal, it is characterized in that can be formed on skeleton, number is different, the bone protuberance to differ in size.When the disease lesion is serious also
Referred to as diaphyseal aclasis, being primarily referred to as disease causes the plastotype for entirely suffering from bone to be abnormal, it might even be possible to all cartilages be enabled to be internalized by
Different degrees of exception occurs for the skeleton of bone.The morbidity of the disease is usually in bilateral symmetric property, be apt to occur in femur, shin bone, fibula,
Humerus, shoulder blade, ilium and rib cage can usually occur at birth, just terminate to grow until puberty.The conjunction of the disease
And disease includes: skeleton deformity, fracture, blood vessel and neurotrosis and canceration is osteosarcoma (incidence is about 5%), patient often needs
Carry out operative treatment.
Currently, thinking that osteochondroma multiple is autosomal dominant disease in the world, most of patients have house
Race's Genetic history.Patient have the probability of half by disease genetic to the next generation, to family and society bring huge stress and
Financial burden.Clinically in addition to symptom is alleviated in operation, still without effective immunotherapy targeted autoantibody method.However, if to patient into
Row gene diagnosis finds out pathogenic mutation, and carries out antenatal consulting and pre-natal diagnosis when patient prepares and gives birth to, then can effectively keep away
The transmitting for exempting from pathogenic mutation allows patient to obtain normal offspring.Therefore, comprehensively, quickly and accurately screening Disease-causing gene is multiple
The important prerequisite condition of property osteochondroma Precise Diagnosis and prevention and treatment.But traditional genetic test side based on Sanger sequencing
For method there are flux low price is expensive, drawback complicated for operation, primary first-order equation can only detect an amplification region, be unable to satisfy and cause a disease more
The requirement for the timeliness that genopathy and multisample detect simultaneously.
Therefore, it is necessary to seek a kind of method of new detection osteochondroma multiple Disease-causing gene mutation, diagnosis is improved
Accuracy rate reduces cost and labor intensity and improves timeliness.
Summary of the invention
To achieve the above object, the present invention provides a kind of DNA library of the Disease-causing gene of osteochondroma multiple, wherein
The library includes at least one gene of serial number 1-8.
Table 1: osteochondroma multiple Disease-causing gene 1
| Serial number | Gene name | OMIM number |
| 1 | COL2A1 | 120140 |
| 2 | CTTNBP2NL | 615100 |
| 3 | EXTL1 | 601738 |
| 4 | EXTL2 | 602411 |
| 5 | IDH1 | 147700 |
| 6 | IDH2 | 147650 |
| 7 | PTPN11 | 176876 |
| 8 | SDC2 | 142460 |
Table 2: osteochondroma multiple Disease-causing gene 2
| Serial number | Gene name | OMIM number |
| 9 | EXT1 | 608177 |
| 10 | EXT2 | 608210 |
| 11 | EXTL3 | 605744 |
| 12 | FGFR3 | 134934 |
| 13 | GRPR | 305670 |
| 14 | PTH1R | 168468 |
| 15 | PTHLH | 168470 |
Preferably, the DNA library includes the gene of serial number 1-8
Preferably, the DNA library further includes at least one gene of serial number 9-15.
It is furthermore preferred that the DNA library includes the gene of serial number 1-15.
The present invention also provides a kind of detection reagents of above-mentioned DNA library.
Preferably, the detection reagent is the primer that can expand above-mentioned DNA library
It is furthermore preferred that the primer is, according to above-mentioned DNA library, design can cover said gene exon and adjoin tune
The primer pond suitable for super-multiplet PCR in region is controlled, so as to carry out super-multiplet PCR amplification to sample genomic dna.
Preferably, the regulatory region of adjoining is each exon edge at least region 5bp.
Preferably, the primer pond carries out the design of super-multiplet PCR amplification by software, so that primary in each reaction tube
Amplification can synchronous parallel expand thousands of amplicons, to carry out high efficiency amplification easy to operate to target area.
The present invention also provides the detection reagents of a kind of above-mentioned DNA library or above-mentioned DNA library to prepare diagnostic kit
In application, the kit is for diagnosing osteochondroma multiple.
The present invention also provides the detection reagents of a kind of above-mentioned DNA library or above-mentioned DNA library in preparing diagnostic device
Application, the diagnostic device is for diagnosing osteochondroma multiple.Preferably, the diagnostic device is genetic chip.
Preferably, the detection reagent is the primer that can expand above-mentioned DNA library.
It is furthermore preferred that the primer is, according to above-mentioned DNA library, design can cover said gene exon and adjoin tune
The primer pond suitable for super-multiplet PCR in region is controlled, so as to carry out super-multiplet PCR amplification to sample genomic dna.
Preferably, the regulatory region of adjoining is each exon edge at least region 5bp.
Preferably, the primer pond carries out the design of super-multiplet PCR amplification by software, so that primary in each reaction tube
Amplification can synchronous parallel expand thousands of amplicons, to carry out high efficiency amplification easy to operate to target area.
It is furthermore preferred that the application includes the following steps:
(1) genomic DNA of subject's sample is provided；
(2) from Ion TorrentTMHigh-flux sequence platform is automatically synthesized the amplimer pond for covering above-mentioned Disease-causing gene,
Super-multiplet PCR amplification is carried out to target area；
(3) digestion is carried out to the amplified production that step (2) obtains；
(4) digestion products obtained to step (3) add Barcode connector, and the Barcode connector is measured from high pass
Sequence builds library kit；
(5) connection product obtained to step (4) purifies；
(6) purified product obtained to step (5) carries out secondary amplification with universal primer, and the universal primer is from high pass
It measures sequence and builds library kit；
(7) Piece Selection and concentration mensuration are carried out to the secondary amplified production that step (6) obtains, that is, builds up patients target area
Domain expands library；
(8) to step (7) obtained library after Water-In-Oil pcr amplification reaction, sequence target fragment to be measured is connected
In ISP pearl, reaction solution is obtained；
(9) reaction solution comprising ISP pearl for obtaining step (8) clicks and enters chip, upper Ion TorrentTMHigh pass measures
Sequence instrument is sequenced；
(10) base sequence information for obtaining step (9) carries out bioinformatics comparison processing, obtains related to disease
Mutational site；
(11) verifying of Sanger PCR sequencing PCR is carried out to the mutational site that step (10) obtains.
Preferably, peripheral blood, body fluid, histoorgan sample of the sample from subject.
It is furthermore preferred that the application is further used for instructing selective fertility, and such as: it is specified by this method multiple
The pathogenic mutation of osteochondroma patient, carries out villus puncture under the premise of patient's pregnant early stage informed consent or amniocentesis obtains tire
Youngster's correlation DNA sample, and detected, to determine whether fetus carries the Disease-causing gene, then decide whether to continue gestation, from
And pathogenic mutation is prevented to pass to the next generation.
The present invention also provides a kind of diagnostic kits, wherein the kit includes the cause of above-mentioned osteochondroma multiple
The detection reagent of the DNA library of ospc gene or above-mentioned DNA library.
The present invention also provides a kind of diagnostic devices, wherein described device includes the pathogenic base of above-mentioned osteochondroma multiple
The detection reagent of the DNA library of cause or above-mentioned DNA library.Preferably, described device is genetic chip.
Preferably, the detection reagent is the primer that can expand above-mentioned DNA library.
It is furthermore preferred that the primer is, according to above-mentioned DNA library, design can cover said gene exon and adjoin tune
The primer pond suitable for super-multiplet PCR in region is controlled, so as to carry out super-multiplet PCR amplification to sample genomic dna.
Preferably, the regulatory region of adjoining is each exon edge at least region 5bp.
Preferably, the primer pond carries out the design of super-multiplet PCR amplification by software, so that primary in each reaction tube
Amplification can synchronous parallel expand thousands of amplicons, to carry out high efficiency amplification easy to operate to target area.
The present invention provides a kind of using above-mentioned DNA library, the detection reagent of DNA library, diagnostic kit or diagnostic device
To the method that patient is detected, the method includes the following steps:
(1) genomic DNA of subject's sample is provided；
(2) from Ion TorrentTMHigh-flux sequence platform is automatically synthesized the amplimer pond of above-mentioned Disease-causing gene, to mesh
It marks region and carries out super-multiplet PCR amplification；
(3) digestion is carried out to the amplified production that step (2) obtains；
(4) digestion products obtained to step (3) add Barcode connector, and the Barcode connector is measured from high pass
Sequence builds library kit；
(5) connection product obtained to step (4) purifies；
(6) purified product obtained to step (5) carries out secondary amplification with universal primer, and the universal primer is from high pass
It measures sequence and builds library kit；
(7) Piece Selection and concentration mensuration are carried out to the secondary amplified production that step (6) obtains, that is, builds up patients target area
Domain expands library；
(8) to step (7) obtained library after Water-In-Oil pcr amplification reaction, sequence target fragment to be measured is connected
In ISP pearl, reaction solution is obtained；
(9) reaction solution comprising ISP pearl for obtaining step (8) clicks and enters chip, and upper Ion TorrentTM high pass measures
Sequence instrument is sequenced；
(10) base sequence information for obtaining step (9) carries out bioinformatics comparison processing, obtains related to disease
Mutational site；
(11) verifying of Sanger PCR sequencing PCR is carried out to the mutational site that step (10) obtains.
(12) mutant of above-mentioned Disease-causing gene if it exists in subject's sample, then subject can be diagnosed as multiple bone
Chondroma.
Preferably, peripheral blood, body fluid, histoorgan sample of the sample from subject.
It is furthermore preferred that the method is further used for instructing selective fertility, and such as: it is specified by this method multiple
The pathogenic mutation of osteochondroma patient, carries out villus puncture under the premise of patient's pregnant early stage informed consent or amniocentesis obtains tire
Youngster's correlation DNA sample, and detected, to determine whether fetus carries the Disease-causing gene, then decide whether to continue gestation, from
And pathogenic mutation is prevented to pass to the next generation.
Using DNA library of the invention to osteochondroma multiple patient carry out gene diagnosis have following significance and
Effect:
1. the DNA library of the application is 15 bases that applicant selects from numerous osteochondroma multiple Disease-causing genes
Cause, these genes are especially suitable for the detection of the yellow race patient including Chinese；Lack in the world at present large-scale
Chinese yellow race's osteochondroma multiple gene diagnosis relevant information, osteochondroma multiple Disease-causing gene known to the overwhelming majority
All mainly from the report of American-European crowd, they are to the pathogenic and feature of Chinese currently without play-by-play.Inventor into
It has gone the gene diagnosis research of long-term clinical observation and extensive Chinese yellow race osteochondroma multiple, has summarized and excavate
The Disease-causing gene of Chinese yellow race osteochondroma multiple patients a series of, and in the world it has been reported that Disease-causing gene
It frequency of disease development in Chinese patients and pathogenic observed and has been verified.It is exhausted big in 15 genes selected by the present invention
Most genes are the Disease-causing gene that inventor verifies and found in yellow race crowd.
2. using based on Ion Torrent in the present inventionTMHigh throughput sequencing technologies carry out the amplified production of target area
Detection, can be detected involved in the present invention simultaneously in once sequencing reaction 15 related genes whole exons and
Contiguous zone, and detection sample size can be adjusted according to the size of different chip data amounts, guaranteeing average sequencing depth
500 × under the premise of, the not equal sample size of 1 to 96 people of detection, entire sequencing reaction and data analysis interpretation can two days it
Interior completion greatly reduces the cost and labor intensity of amplified reaction, improves timeliness, meanwhile, which, which has, covers
Cover degree is wide, and whole coverage reaches 99.5%；.By sequencing to target amplification region and data interpretation, can accurately identify
Mutation relevant to disease, judges kinds of Diseases and the cause of disease, provides timely reliable examining report for clinic.What the present invention designed
Detection method is verified by Sanger PCR sequencing PCR, 100 is reached to two generations sequencing depth × point mutation, the accuracy of this method reaches
To 100%；
3. gene diagnosis facilitates pre-natal diagnosis and neonatal screening etc..Because of osteochondroma multiple, patient will face one in future
Serial severe complication, and there is no effective radical cure method, heavy medical burden is brought to patient home and society.Patient
Household pays special attention to the health of patient offspring.Osteochondroma multiple is that often dyeing dominant hereditary disease, patient offspring have 50%
Initiation potential.The mutation of patient's Disease-causing gene is made a definite diagnosis, and can provide specific genetic counselling clothes to breed the next generation of health
Business.
4. including 15 correlations of causing a disease it is furthermore preferred that the present invention provides the cause of disease known to covering osteochondroma multiple comprehensively
The DNA library of Disease-causing gene.This 15 gene selects are based on the clinical Disease-causing gene database reported and generally acknowledged based on the world
The subject study content of (omim database, HGMD database, ClinVar database) and inventor oneself.This 15 genes
On pathogenic mutation both can individually cause a disease, can also mutually Combination pathogenicity lead to more serious and complicated clinical phenotypes,
Invention is accomplished disposably comprehensively they to be sequenced for the first time, is to be currently known to cause a disease base for osteochondroma multiple
Because covering a kind of most comprehensive targeting sequencing detection.
In general, the DNA library involved in the present invention, the detection reagent of DNA library and its application have accurate, spirit
Feature living, quickly, inexpensive；By clinical assessment, which has good auxiliary diagnosis valence to osteochondroma multiple
Value.
Detailed description of the invention
Ion Torrent of Fig. 1TMThe data of high-flux sequence reaction acquire synoptic diagram
Fig. 2 is once sequenced the target area of 15 genes, the data amount information that different specimens obtain
Fig. 3 is after primary data analysis, the mutating alkali yl quantity of obtained different specimens
Fig. 4 Sanger PCR sequencing PCR verifies the mutational site that detection method obtains
Specific embodiment
The invention will be further described With reference to embodiment, not to the restriction of invention, according to this field
The well known prior art, embodiments of the present invention are not limited to this, therefore all according to this field made by present disclosure
Equivalent replacement, all belong to the scope of protection of the present invention.
Embodiment 1
1. used reagent in this method:
Ion AmpliSeqTMLibrary Kit 2.0, Ion PGMTMTemplate OT2 200Kit v3, IonSequencing 200Kit v2, Ion Xpress Barcode Adaptors 1-16Kit, Ion 318TM Chip
Kit v2
2. collection of specimens and preservation
(1) collection of specimens: sample is peripheral blood in patients.Blood is conventional extracting vein blood 5ml, EDTA anticoagulation.
(2) it saves: can detect immediately, 4 DEG C save one week, -80 DEG C of preservations more than one week.
3. detecting step and interpretation of result:
(1) extraction of sample genomic DNA: the extraction of specimen dna is according to TIANGEN Biotech (Beijing) Co., Ltd.
Blood DNA extracts kit operating instruction carries out.
(2) the super-multiplet PCR amplification and Jian Ku of object detection area: with 15 full exons of gene involved in the present invention
For detection zone, it is based on Ion AmpliSeqTMDesigner is automatically synthesized super-multiplet PCR primer, to the target area of specimen dna
Domain is expanded and is built library, is embodied as follows:
A. the amplification of target area:
Reaction condition:
B. amplified production is two-in-one, digestion:
Reaction condition:
C. jointing:
Reaction condition:
22℃ 30min
72℃ 10min
10℃ Up to 1h
D. purifying and the secondary amplification of purified product: purification step is according to Ion Ampliseq Library
Preparation operation manual carries out, and final product is dissolved in 52 μ l reaction systems, reaction system composition are as follows:
Reaction condition:
E. Piece Selection: Piece Selection step according to Ion Ampliseq Library Preparation operation manual into
Capable, library completion is built in finally building after library product Qubit 2.0Fluorometer is quantified for obtaining.
(3) high-flux sequence: sequencing and early-stage preparations step are according to Ion PGMTMTemplate OT2 200Kit v3 and
Ion Sequencing 200Kit v2 operation manual carries out:
A. Water-In-Oil PCR reacts:
Above-mentioned reaction system is added in Ion OneTouch 2 and carries out Water-In-Oil PCR reaction.
B. Water-In-Oil PCR after the reaction was completed, is connected with the Ion PGM Template OT2 200Ion of sequencing template
Sphere Particles is purified by Ion Onetouch ES, and sequencing primer and archaeal dna polymerase is added:
After room temperature 5min, the obtained reaction solution comprising ISP pearl is clicked and entered into chip, upper Ion TorrentTM is high-throughput
Sequenator is sequenced.
(4) data are analyzed: sequencing data is analyzed by coverage analysis and variant caller, obtains alkali
Basic sequence and mutational site, by Ion Reporter after line annotation, obtaining diagnosing genetic cardiomyopathies has in mutational site
The mutational site of meaning.
(5) Sange method is verified: for obtained mutational site, being verified using Sanger PCR sequencing PCR.
As a result illustrate and analyze
High throughput sequencing technologies involved in through the invention disposably detect (such as the target area of 3 samples
Fig. 1), the total amount of data obtained is 797M (Total Base), and the segment that can be always obtained 5,214,030 reads long data
Read a length of 140bp in the middle position of (Total Reads), each segment.3 samples can averagely be measured 571,129 (510,003-
634,564) a segment reads long Reads (such as Fig. 2), and the above sequencing result provides sufficient data for the sequence analysis of next step
Amount.Sequencing result is analyzed by variant Caller, and each sample averagely has 55 variations (Variants) to be read (as schemed
3).Through Ion Reporter after line annotation, mutational site relevant to disease is surveyed by Sanger for the variation of detection zone
Sequence method verify (such as Fig. 4), as Fig. 4 is enumerated, shown at Fig. 4 arrow meaning EXT1 gene c.79C > T
(p.Gln27Ter) heterozygosis nonsense mutation, the genetic defect type of final clear patient, provides diagnosis basis for clinic.Simultaneously should
Gene genetic mode is autosomal dominant inheritance, and the siblings and its children of patient have 50% probability and patient one
Sample carries the pathogenic mutation, also faces onset risk, should carry out the screening of the pathogenic sites, for the following selectivity fertility and produces
Preceding diagnosis provides foundation.
Clinical application illustration of the invention
Using method provided by the present invention, to 50 with osteochondroma multiple but the true patient of etiology unknown carries out
Genetic test.Patient 48 of pathogenic mutation are found altogether.This method reaches the total positives rate that osteochondroma multiple detects
96%, in conjunction with clinical manifestation, imageological examination and doctor's last diagnostic are as a result, the false positive rate of this method is 0, i.e., all warps
The carrying pathogenic mutation patient of this method confirmation meets the Clinical symptoms of correlated inheritance disease, and can give specific clinic
Diagnosis.Detection method of the present invention is to be sequenced using high throughput sequencing technologies to be mutated quick screening implement with Sanger
Method is the final goldstandard for determining mutation, therefore has fast and accurate feature.With high-flux sequence mean depth 100 × be
Example, 94.99% target area covered can be sequenced, and the point mutation that screening obtains can be by Sanger PCR sequencing PCR
Verifying, therefore be 100% to the accuracy of area above detection.According to the clinic diagnosis interpretation of result of 50 tested patients, by
It surveys patient and does not occur false negative rate.The approval of clinician is obtained based on the diagnosis report that detection method of the present invention provides
With adopt.It is accurate that detection method of the present invention has, quickly, inexpensive feature, the diagnosis to osteochondroma multiple
Important in inhibiting and practical value.In 50 patients, complex mutation is had found in 2 patients, two patient clinical tables
Type and age of onset are aggravated.It would therefore be desirable to comprehensive Disease-causing gene scanning be carried out to patient, with more accurately right
Its pathogenesis is analyzed, thus for from now on clinical treatment and genetic counselling lay the foundation.
Embodiment 2:
It include the newfound osteochondroma multiple Disease-causing gene of inventor 8 in primer pond in the present invention.Such as above-mentioned table 1
It is shown.Research accumulation and family line investigation of the newfound 8 osteochondroma multiple Disease-causing genes from inventor for many years.
Inventor is retrieved in known osteochondroma multiple Disease-causing gene by KEGG signal path first, and homologous gene library is sought
The homologous gene and the key gene on identical pathogenic access for looking for known Disease-causing gene.Then in the Chinese yellow people of many years accumulation
Targeting high-flux sequence is carried out to candidate Disease-causing gene in kind patient's large sample size case sample database, and carries out bioinformatics
Analysis, screening and searching pathogenic mutation.Follow-up and further pedigree analysis are carried out to the case for screening pathogenic mutation, to trouble
The entire family of person carries out pathogenic sites sequence verification, and calculate pathogenic mutation isolates coefficient.When the cause of discovery candidate gene
Disease mutation can tentatively judge that the candidate disease causing genes are newly when isolating completely in the family of two or more onrelevant
Disease-causing gene.It is a discovery of the invention that the pathogenic mutation of above-mentioned 8 genes occurs completely in the family of two or more onrelevant
It isolates.
Claims (13)
1. a kind of DNA library for diagnosing osteochondroma multiple, which is characterized in that the library includes the gene of serial number 1-8,
In, the gene of serial number 1-8 is as follows:
。
2. DNA library as described in claim 1, which is characterized in that the DNA library further includes at least the one of serial number 9-15
A gene, wherein the gene of serial number 9-15 is as follows:
。
3. DNA library as claimed in claim 2, which is characterized in that the DNA library includes the gene of serial number 1-15,
In, the gene of serial number 1-15 is as follows:
4. a kind of detection reagent of any DNA library of claim 1-3.
5. detection reagent as claimed in claim 4, which is characterized in that the detection reagent is to expand above-mentioned DNA library
Primer.
6. detection reagent as claimed in claim 5, which is characterized in that the primer is, according to above-mentioned DNA library, to design energy
Covering said gene exon and the primer pond suitable for super-multiplet PCR for adjoining regulatory region, so as to sample genome
DNA carries out super-multiplet PCR amplification.
7. any any detection reagent of the DNA library or claim 4-6 of claim 1-3 is diagnosed in preparation
Application in kit, which is characterized in that the kit is for diagnosing osteochondroma multiple.
8. any any detection reagent of the DNA library or claim 4-6 of claim 1-3 is diagnosed in preparation
Application in device, which is characterized in that the diagnostic device is for diagnosing osteochondroma multiple.
9. application as claimed in claim 8, which is characterized in that the diagnostic device is genetic chip.
10. the application as described in claim 7-9 any claim, which is characterized in that the application includes the following steps:
(1) genomic DNA of subject's sample is provided；
(2) from Ion TorrentTMHigh-flux sequence platform is automatically synthesized the amplimer pond for covering above-mentioned Disease-causing gene, to mesh
It marks region and carries out super-multiplet PCR amplification；
(3) digestion is carried out to the amplified production that step (2) obtains；
(4) digestion products obtained to step (3) add Barcode connector；
(5) connection product obtained to step (4) purifies；
(6) purified product obtained to step (5) carries out secondary amplification with universal primer；
(7) Piece Selection and concentration mensuration are carried out to the secondary amplified production that step (6) obtains, that is, builds up the expansion of patients target region
Increase library；
(8) to step (7) obtained library after Water-In-Oil pcr amplification reaction, sequence target fragment to be measured is connected to ISP
Pearl obtains reaction solution；
(9) reaction solution comprising ISP pearl for obtaining step (8) clicks and enters chip, upper Ion TorrentTMHigh-flux sequence instrument
It is sequenced；
(10) base sequence information for obtaining step (9) carries out bioinformatics comparison processing, obtains relevant to disease prominent
Displacement point；
(11) verifying of Sanger PCR sequencing PCR is carried out to the mutational site that step (10) obtains.
11. a kind of diagnostic kit, which is characterized in that the kit include any DNA library of claim 1-3 or
Any detection reagent of person's claim 4-6.
12. a kind of diagnostic device, which is characterized in that described device includes claim the 1-3 any DNA library or power
Benefit requires any detection reagent of 4-6.
13. diagnostic device as claimed in claim 12, which is characterized in that the diagnostic device is genetic chip.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610785555.0A CN106676637B (en) | 2016-08-31 | 2016-08-31 | A kind of DNA library and its application detecting osteochondroma multiple Disease-causing gene |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610785555.0A CN106676637B (en) | 2016-08-31 | 2016-08-31 | A kind of DNA library and its application detecting osteochondroma multiple Disease-causing gene |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106676637A CN106676637A (en) | 2017-05-17 |
| CN106676637B true CN106676637B (en) | 2019-06-18 |
Family
ID=58839348
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610785555.0A Active CN106676637B (en) | 2016-08-31 | 2016-08-31 | A kind of DNA library and its application detecting osteochondroma multiple Disease-causing gene |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106676637B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112501286A (en) * | 2020-12-30 | 2021-03-16 | 上海交通大学医学院附属瑞金医院 | Marker of genetic thyroid dysfunction disease pathogenic gene and detection kit thereof |
| WO2023272672A1 (en) * | 2021-07-01 | 2023-01-05 | 北京市肿瘤防治研究所 | Rapid screening apparatus for germline mutations of tumor susceptibility genes in mixed samples and application |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2914272A4 (en) * | 2012-11-02 | 2016-11-30 | Univ Rochester | Heparanase and its uses related to exostoses |
| CN103834673B (en) * | 2012-11-26 | 2018-09-04 | 深圳华大基因股份有限公司 | EXT1 gene mutation bodies and its application |
| CN103157040A (en) * | 2013-03-31 | 2013-06-19 | 曹伟 | Pharmaceutical composition for treating multiple osteoenchondroma |
| CN104313698B (en) * | 2014-10-29 | 2020-05-12 | 华中科技大学同济医学院附属同济医院 | DNA library for detecting cholestatic jaundice pathogenic gene and application thereof |
-
2016
- 2016-08-31 CN CN201610785555.0A patent/CN106676637B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN106676637A (en) | 2017-05-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105506115B (en) | A kind of DNA library and its application of checkout and diagnosis genetic cardiomyopathies Disease-causing gene | |
| CN105442052B (en) | A kind of DNA library of checkout and diagnosis dissection of aorta disease Disease-causing gene and its application | |
| CN106350589B (en) | A kind of DNA library and its application detecting inherited vascular diseases Disease-causing gene | |
| CN106544407B (en) | The method for determining donor source cfDNA ratio in receptor cfDNA sample | |
| CN102939389B (en) | Diagnostic method based on the acquired rearrangement of somatic cell | |
| CN106319058B (en) | A kind of DNA library and its application detecting idiopathic pulmonary fibrosis Disease-causing gene | |
| CN105543361B (en) | A kind of DNA library and its application of checkout and diagnosis polycystic kindey Disease-causing gene | |
| CN102965428A (en) | Kit for testing and identifying genetic cardiac hypertrophy related gene mutation | |
| CN104313698B (en) | DNA library for detecting cholestatic jaundice pathogenic gene and application thereof | |
| CN105132407B (en) | A kind of cast-off cells DNA low frequencies mutation enrichment sequence measurement | |
| KR101801871B1 (en) | Method for prediction of fetal monogenic genetic variations using maternal cell-free dna | |
| CN106480170B (en) | Determine the method and application of donor and receptor difference SNP | |
| CN109411015A (en) | Tumor mutations load detection device and storage medium based on Circulating tumor DNA | |
| CN107075564A (en) | The method and apparatus for determining tumour nucleic acid concentration | |
| CN113096728B (en) | Method, device, storage medium and equipment for detecting tiny residual focus | |
| CN105040111A (en) | Construction method of systemic lupus erythematosus map model | |
| CN106399304B (en) | A kind of SNP marker relevant to breast cancer | |
| CN106995851A (en) | Expand PCR primer, the kit of detection PKD1 gene mutations and the application of PKD1 extron overlength fragments | |
| CN108949979A (en) | A method of judging that Lung neoplasm is good pernicious by blood sample | |
| CN106676637B (en) | A kind of DNA library and its application detecting osteochondroma multiple Disease-causing gene | |
| GB2559437A (en) | Prenatal screening and diagnostic system and method | |
| CN105442053B (en) | A kind of DNA library of checkout and diagnosis ion channel disease Disease-causing gene and its application | |
| CN116631508B (en) | Detection method for tumor specific mutation state and application thereof | |
| US11869630B2 (en) | Screening system and method for determining a presence and an assessment score of cell-free DNA fragments | |
| CN105986032A (en) | Kit, library establishment method, and method and system for detecting target region variation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |